FAIRFAX, Va., Aug. 26 /PRNewswire-USNewswire/ — Recognizing
that venous interventions may potentially play an important role in
treating some patients who suffer from multiple sclerosis — an
incurable, disabling disease — the Society of Interventional
Radiology has issued a position statement indicating its support
for high-quality clinical research to determine the safety and
effectiveness of interventional M.S. treatments. SIR’s
position statement is endorsed by the Canadian
Interventional Radiology Association and will be published in the
September Journal of Vascular and Interventional Radiology.
(Logo: http://photos.prnewswire.com/prnh/20100127/SIRLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20100127/SIRLOGO)
“The Society of Interventional Radiology would like to be
actively involved in developing evidence-based therapies for the
potential treatment of patients with multiple sclerosis,” said SIR
President James F. Benenati, M.D., FSIR. “Completing high-quality
studies — for example, on chronic cerebrospinal venous
insufficiency (CCSVI, a reported abnormality in blood drainage from
the brain and spinal cord) and interventional M.S. treatments —
should be a research priority for investigators, funding agencies
and M.S. community advocates,” added Benenati, who represents
nearly 4,700 doctors, scientists and allied health professionals
dedicated to improving health care through minimally invasive
treatments.
About 500,000 people in the United States have M.S., and SIR
understands the public’s desire to advance treatment for M.S.,
generally thought of as an autoimmune disease in which a person’s
body attacks its own cells. Currently, medicines may slow the
disease and help control symptoms. The role of CCSVI in M.S. and
its endovascular treatment (through a catheter placed in a
vein
‘/>”/>
SOURCE
